- $75.24m
- $48.63m
- $16.89m
- 59
- 14
- 39
- 30
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.83 | ||
| Price to Tang. Book | 3.81 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 5.1 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -91.57% | ||
| Return on Equity | -80.11% | ||
| Operating Margin | -207.9% | ||
Financial Summary
| Year End 30th Sep | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 42.59 | 61.26 | 39.35 | 16.3 | 16.89 | 2.9 | n/a | -11.89% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Veru Inc. is a late clinical-stage biopharmaceutical company focused on developing medicines for the treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its drug development program includes two late-stage novel small molecules: enobosarm and sabizabulin. Enobosarm, a selective androgen receptor modulator, is being developed for two indications: Phase 2b clinical QUALITY study of enobosarm as a treatment to augment fat loss and to prevent muscle loss in sarcopenic obese or overweight elderly patients receiving a GLP-1 RA who are at-risk for developing muscle atrophy and muscle weakness, and Phase 3 ENABLAR-2 clinical trial of enobosarm and abemaciclib for the treatment of androgen receptor positive, estrogen receptor positive and human epidermal growth factor receptor 2 negative metastatic breast cancer in the 2nd line setting. Sabizabulin, a microtubule disruptor, is being developed for treatment of hospitalized patients with viral-induced ARDS.
Directors
- Mitchell Steiner CHM (61)
- Harry Fisch VCH (63)
- Michele Greco CFO (63)
- K. Barnette CSO (54)
- Mario Eisenberger IND (72)
- Grace Hyun IND (50)
- Lucy Lu IND (46)
- Michael Rankowitz IND (63)
- Last Annual
- September 30th, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- February 4th, 1971
- Public Since
- July 19th, 1990
- No. of Shareholders
- 148
- No. of Employees
- 210
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
NASDAQ Capital Market- Shares in Issue
- 146,383,920
- Address
- 2916 N. MIAMI AVENUE, SUITE 1000, MIAMI, 33127
- Web
- https://verupharma.com/
- Phone
- +1 3125959123
- Contact
- Samuel Fisch
- Auditors
- RSM US LLP
Latest News for VERU
Upcoming Events for VERU
Q2 2025 Veru Inc Earnings Call
Q2 2025 Veru Inc Earnings Release
Veru Inc Annual Shareholders Meeting
Q3 2025 Veru Inc Earnings Release
Similar to VERU
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
Aclarion
NASDAQ Capital Market
FAQ
As of Today at 23:58 UTC, shares in Veru are trading at $0.51. This share price information is delayed by 15 minutes.
Shares in Veru last closed at $0.51 and the price had moved by -68.66% over the past 365 days. In terms of relative price strength the Veru share price has underperformed the S&P500 Index by -71.74% over the past year.
The overall consensus recommendation for Veru is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreVeru does not currently pay a dividend.
Veru does not currently pay a dividend.
Veru does not currently pay a dividend.
To buy shares in Veru you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $0.51, shares in Veru had a market capitalisation of $75.24m.
Here are the trading details for Veru:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: VERU
Based on an overall assessment of its quality, value and momentum Veru is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Veru is $2.75. That is 435.02% above the last closing price of $0.51.
Analysts covering Veru currently have a consensus Earnings Per Share (EPS) forecast of -$0.23 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Veru. Over the past six months, its share price has underperformed the S&P500 Index by -32.37%.
As of the last closing price of $0.51, shares in Veru were trading -27.78% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Veru PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.51.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Veru's management team is headed by:
- Mitchell Steiner - CHM
- Harry Fisch - VCH
- Michele Greco - CFO
- K. Barnette - CSO
- Mario Eisenberger - IND
- Grace Hyun - IND
- Lucy Lu - IND
- Michael Rankowitz - IND